Asthma - Versorgungsleitlinien.de

NVL Asthma, 2. Auflage
Langfassung
Juli 2011, Version 1.3
355. Lemanske RF, Jr., Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, Drazen JM,
Chinchilli VM, Craig T, Fish JE, Ford JG, Israel E, Kraft M, Martin RJ, Nachman SA, Peters
SP, Spahn JD, Szefler SJ. Inhaled corticosteroid reduction and elimination in patients with
persistent asthma receiving salmeterol: a randomized controlled trial. JAMA
2001;285(20):2594-603.
356. Buhl R, Creemers JP, Vondra V, Martelli NA, Naya IP, Ekstrom T. Once-daily
budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir
Med 2003;97(4):323-30.
357. Fitzgerald JM, Boulet LP, Follows RM. The CONCEPT trial: a 1-year, multicenter,
randomized,double-blind, double-dummy comparison of a stable dosing regimen of
salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of
formoterol/budesonide in adults with persistent asthma. Clin Ther 2005;27(4):393-406.
358. Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid
to prevent asthma exacerbations: randomised controlled trial. Lancet 2004;363(9405):271-5.
359. Humbert M, Andersson TL, Buhl R. Budesonide/formoterol for maintenance and reliever therapy
in the management of moderate to severe asthma. Allergy 2008;63(12):1567-80.
360. Reddel HK, Jenkins CR, Marks GB, Ware SI, Xuan W, Salome CM, Badcock CA, Woolcock AJ.
Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J
2000;16(2):226-35.
361. ten Brinke A, Sterk PJ, Masclee AA, Spinhoven P, Schmidt JT, Zwinderman AH, Rabe KF, Bel
EH. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J
2005;26(5):812-8.
362. Weiler JM, Bonini S, Coifman R, Craig T, Delgado L, Capao-Filipe M, Passali D, Randolph C,
Storms W. American Academy of Allergy, Asthma & Immunology Work Group report:
exercise-induced asthma. J Allergy Clin Immunol 2007;119(6):1349-58.
363. Godfrey S, Bar-Yishay E. Exercised-induced asthma revisited. Respir Med 1993;87(5):331-44.
364. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lotvall J. Inhaled dry-powder
formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and
potency. Eur Respir J 1997;10(11):2484-9.
365. Ferrari M, Segattini C, Zanon R, Bertaiola M, Balestreri F, Brotto E, Lo C, V. Comparison of the
protective effect of formoterol and of salmeterol against exercise-induced bronchospasm
when given immediately before a cycloergometric test. Respiration 2002;69(6):509-12.
366. Newnham DM, Ingram CG, Earnshaw J, Palmer JB, Dhillon DP. Salmeterol provides prolonged
protection against exercise-induced bronchoconstriction in a majority of subjects with mild,
stable asthma. Respir Med 1993;87(6):439-44.
367. Richter K, Janicki S, Jorres RA, Magnussen H. Acute protection against exercise-induced
bronchoconstriction by formoterol, salmeterol and terbutaline. Eur Respir J 2002;19(5):865-
71.
368. Shapiro GS, Yegen U, Xiang J, Kottakis J, Della CG. A randomized, double-blind, single-dose,
crossover clinical trial of the onset and duration of protection from exercise-induced
bronchoconstriction by formoterol and albuterol. Clin Ther 2002;24(12):2077-87.
Gilt nur für
Erwachsene
Gilt nur für
Kinder/Jugendliche
Allgemeine
Empfehlungen
© 2009 226